Good news of another £1m award to repurpose an oncology drug into RA.
The drug is a small molecule cyclin-dependent kinase inhibitor developed by Dundee-based biotech, Cyclacel.
The key hypothesis is that the ‘quasi-malignant’ synovial fibroblast provides the explanation that few patients achieve remission using biologic drugs.
This is the first ever trial to specifically target this cell type in RA.
Newcastle to be the lead site with collaborators in Glasgow and Birmingham.
Post a Comment
Note: only a member of this blog may post a comment.